CPLX4

Across TCGA pan-cancer cohorts, CPLX4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CPLX4 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CPLX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPLX4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD and UCEC are the cancer types where CPLX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.001	0.633	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.042	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CPLX4–STAD (OS)

Open the STAD breakdown →